Skip to main content
Equibles
LNSR logo

LNSR · LENSAR, Inc. · Metrics

Track LNSR — free

Use LNSR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LNSR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.60 -0.45 (-5.59%) At close · Sep 11
Rebalance outlook locked
Customer concentration — top customer 14% of revenue

One customer — 14% of revenue (the three months ended March 31, 2026)

“For the three months ended March 31, 2026, one customer accounted for approximately 14% of our revenue.”

One customer — 12% of receivables (As of March 31, 2026)

“As of March 31, 2026, one customer accounted for approximately 12% of our accounts receivable, net.”
View the 10-Q filed May 8, 2026
Market Cap
$93.37M
Shares
12.29M

LNSR metrics

61 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$7.60
Market cap
$93.37M

Price action

20 metrics
Price change (1W)
-11.4%
Price change (30D)
-7.3%
Price change (3M)
+30.6%
Price change (6M)
-22.8%
Price change (YTD)
-34.7%
Price change (1Y)
-37.3%
Trailing year
Price change (5Y)
-7.3%
52-week high
$12.73
52-week low
$5.01
Change from 52-week high
-40.3%
Change from 52-week low
+51.7%
Annualized volatility
66.9%
Annualized volatility (3M)
84.3%
Beta
0.6
RSI (14D)
46.5
Price vs SMA 50
+10.5%
Price vs SMA 200
-8.4%
Avg volume (3M)
125,507
Relative volume
0.7
Average dollar volume
$915,674

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
12.29M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.5×
reciprocal yield 64.5%
P / book
6.3
reciprocal yield 16.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
37.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
48.3%
Operating margin
-13.5%
Trailing 12 months
Net margin
57.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$8.13M
Net income (TTM)
$34.70M
Trailing 12 months
Diluted EPS (TTM)
$-0.30
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-2.17

Growth

11 metrics
Revenue growth YoY
+18.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$60.26M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+92.9%
Year over year · more shares
Revenue CAGR (3Y)
+18.2%
Revenue CAGR (5Y)
+17.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
232.8%
Return on assets
49.9%
Debt / equity
—
Current ratio
2.4
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$13.56M
Latest balance sheet
Cash & equivalents
$13.56M
Total assets
$69.56M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$7.29M
Capital expenditures (TTM)
$35,000
R&D (TTM)
$5.32M
SG&A (TTM)
$31.02M
Stock compensation (TTM)
$2.76M
R&D / revenue
8.8%
Stock compensation / revenue
4.6%

Ownership (13F)

3 metrics
13F filers
74
13F filer change QoQ
-14
Institutional ownership
35.7%

Short interest

3 metrics
Short interest
3.1%
Latest settlement · 3.0 days to cover
Days to cover
3.0d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1320350 CUSIP 52634L108 13F (30d) 2 filings 2 filers Visit website Investor relations